Form 8-K BIOLASE, INC For: Aug 05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): | August 5, 2015 |
Biolase, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Delaware | 000-19627 | 87-0442441 |
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
of incorporation) | File Number) | Identification No.) |
4 Cromwell, Irvine, California | 92618 | |
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
Registrants telephone number, including area code: | 949-361-1200 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2015, Biolase, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2015. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
d) Exhibits.
99.1 Press Release of Biolase, Inc., dated August 5, 2015.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Biolase, Inc. | ||||
August 5, 2015 | By: |
David C. Dreyer
|
||
|
||||
Name: David C. Dreyer | ||||
Title: SVP and Chief Financial Officer |
Exhibit Index
Exhibit No. | Description | |
|
|
|
99.1
|
Press Release of Biolase, Inc., dated August 5, 2015. |
BIOLASE REPORTS 2015 SECOND QUARTER RESULTS
IRVINE, CA (August 5, 2015) BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported its financial results for the second quarter and six months ended June 30, 2015.
Selected highlights of the 2015 second quarter include: |
||||
|
||||
| Worldwide revenue grew $1.7 million, or 17%, year-over-year and 9% sequentially. |
| U.S. revenue increased 17% year-over-year, including a 47% increase in WaterLase® sales. |
| International revenue increased 16% year-over-year, including a 35% increase in WaterLase® sales. |
| Laser systems revenue worldwide increased $1.4 million, or 22%, year-over-year and 11% sequentially, including a 42% increase year-over-year and 21% sequentially, related to WaterLase® systems. |
| Imaging revenue worldwide decreased $0.2 million, or 23%, year-over-year. |
| Achieved double digit worldwide growth of consumables revenue. |
| Cash burn of $3.8 million, a 50% reduction from previous quarter. |
New President and CEO Harold Flynn, Jr., who joined BIOLASE in mid-July, stated that the Company demonstrated meaningful growth in its core laser franchises in the second quarter. This was especially true in the U.S. where our primary laser products and related consumable products all showed positive growth year-over-year and sequentially.
Our Practice Growth. Guaranteed initiative is resonating well with new customers, Flynn added. This unique initiative focuses on the training of new customers in the safe and effective use of their WaterLase® iPlus 2.0 system to improve and enhance treatment of their patients. The program also provides education on how to take full advantage of the many indications offered by our laser system to practice better dentistry and thereby grow their practice and its revenue. We continue to invest heavily in additional innovative laser-based solutions to extend our leadership within laser dentistry, emphasizing better patient care, excellent customer service and new products that better meet the needs of patients and dental professionals.
Second Quarter and Six-Month Financial Results
Net revenue for the second quarter of 2015 was $11.9 million, compared to net revenues of $10.2
million for the second quarter of 2014. The quarter-over-quarter increase of 17% was principally
due to increases in domestic and international laser systems, consumables and service revenue,
partially offset by decreases in domestic imaging systems revenue.
Net revenue for the six months ended June 30, 2015 was $22.7 million, compared to net revenues of $21.7 million for the six months ended June 30, 2014. The overall year-over-year increase in net revenue primarily resulted from increases in domestic and international laser system and consumable revenue, partially offset by decreases mostly in domestic imaging systems revenue. Worldwide year-to-date imaging revenue through June 30, 2015, was $900 thousand, down $1.0 million or 54%, compared to the same period last year.
Gross profit as a percentage of revenue typically fluctuates with product and regional mix, selling prices, material costs and revenue levels. Gross profit as a percentage of net revenue for the second quarter and first six months of 2015 was 31.2% and 30.4%, respectively, compared to 36.6% and 35.3%, respectively, for the same prior year periods. The decline was mainly attributable to increased international sales volume and increased promotions related to this years launches of the WaterLase® iPlus 2.0 and EPIC X. Second quarter and first-half 2015 gross profit related to international sales denominated in foreign currency was negatively impacted by the stronger U.S. dollar when compared with the same prior year periods.
Total operating expenses in the second quarter and six months ended June 30, 2015 were $10.7 million and $19.2 million, respectively, compared to $9.9 million and $18.5 million for the same prior year periods. The increases in this years operating expenses for the second quarter and six months were due to a combination of increased spending in engineering and development for new product development and support of existing products and technologies, along with increased spending in sales and marketing on product promotions and building brand awareness. These increases were partially offset by decreased spending in general and administrative expenses attributable to decreased legal expenses and professionals fees, and a credit related to a favorable legal settlement with a competitor recorded in the first quarter of 2015.
The net loss for the second quarter and six months ended June 30, 2015 was $7.0 million and $12.5 million, respectively, or a $0.12 and $0.21 loss per share, respectively, compared to a net loss of $6.4 million and $11.3 million, or $0.17 and $0.31 loss per share, for the same prior year periods. The increase in net loss was primarily due to lower gross profit margins and increased operating expenses in 2015 when compared to 2014.
After removing interest income, net of $23 thousand, income tax provision of $36 thousand, non-cash depreciation and amortization expenses of $166 thousand and non-cash stock-based compensation expenses of $935 thousand, the adjusted non-GAAP net loss for this years second quarter totaled $5.9 million, or a loss of $0.10 per share, compared with a non-GAAP net loss of $5.7 million, or a loss of $0.15 per share, during the prior year second quarter. The non-GAAP net loss totaled $10.5 million, or a loss of $0.18 per share, for the six months ended June 30, 2015 compared with a non-GAAP net loss of $9.8 million, or a loss of $0.26 per share, for the same prior year period.
Liquidity and Capital Resources
As of June 30, 2015, BIOLASE had approximately $27.3 million in working capital. Cash and cash
equivalents at the end of the second quarter of 2015 were $20.1 million, compared to $31.6 million
on December 31, 2014. Net accounts receivable totaled $9.8 million at June 30, 2015, as compared
to $9.0 million at December 31, 2014.
Senior Vice President and Chief Financial Officer David Dreyer stated the Companys cash and cash equivalents total of $20.1 million as of June 30, 2015 reflected a reduction of $11.4 million during the first six months of 2015. This reduction consisted of a decrease of $7.6 million during the first quarter 2015 followed by a decrease of $3.8 million during the second quarter 2015. The decrease in cash and equivalents during the 2015 second quarter was half the decrease amount during the first quarter of this year, reflecting managements increased focus and attention on better managing its uses of cash.
Conference Call
As previously announced, the Company will host a conference call today at 4:30 p.m. Eastern Time to
discuss its operating results for the second quarter and six months ended June 30, 2015, and to
answer questions. To listen to the conference call live via telephone, dial 1-877-407-4019
from the U.S. or, for international callers, dial 1-201-689-8337, approximately 10 minutes
before the start time. To listen to the conference call live via the Internet, visit the Investors
section of the BIOLASE website at www.biolase.com.
About BIOLASE, Inc.
BIOLASE, Inc. is a medical device company that develops, manufactures, and markets innovative
lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital
imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3D printers.
BIOLASEs products are focused on technologies that advance the practice of dentistry to both the
dentist and their patients. The Companys proprietary laser products incorporate approximately 185
patented and 115 patent-pending technologies designed to provide biologically clinically superior
performance with less pain and faster recovery times. Its innovative products provide cutting-edge
technology at competitive prices to deliver the best results for dentists and patients. BIOLASEs
principal products are revolutionary dental laser systems that perform a broad range of dental
procedures, including cosmetic and complex surgical applications, and a full line of dental imaging
equipment. BIOLASE has sold more than 29,000 laser systems. Laser products under development
address the Companys core dental market and other adjacent medical and consumer markets.
For updates and information on WaterLase® iPlus and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.
BIOLASE® and WaterLase® are registered trademarks of BIOLASE, Inc.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements contained in this press release that refer to BIOLASEs estimated or anticipated future
results or other non-historical facts are forward-looking statements, as are any statements in this
press release concerning prospects related to BIOLASEs strategic initiatives and anticipated
financial performance. Forward-looking statements can also be identified through the use of words
such as anticipates, expects, intends, plans, believes, seeks, estimates, may,
will, and variations of these words or similar expressions. Readers are cautioned not to place
undue reliance on these forward-looking statements, which reflect BIOLASEs current expectations
regarding existing trends, our strategic initiatives, the closing of the private placement and
expected use of proceeds and speak only as of the date of this release. Actual results may differ
materially from BIOLASEs current expectations depending upon a number of factors affecting
BIOLASEs business. These factors include, among others, adverse changes in general economic and
market conditions, competitive factors including but not limited to pricing pressures and new
product introductions, uncertainty of customer acceptance of new product offerings and market
changes, risks associated with managing the growth of the business, and those other risks and
uncertainties that may be detailed, from time-to-time, in BIOLASEs reports filed with the SEC.
BIOLASE does not undertake any responsibility to revise or update any forward-looking statements
contained herein.
For further information, please contact:
BIOLASE, Inc. | DresnerAllenCaron | |
David Dreyer Chief Financial Officer |
Rene Caron (Investors) 949-474-4300 |
[email protected] [email protected]
888-424-6527 | ||
(Financial Tables Follow)
BIOLASE, INC. | ||||||||||||||||||||||||||||||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||||||||||||||||||||||||||||||
(unaudited, in thousands, except per share data) | ||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||||||||
June 30 | June 30 | |||||||||||||||||||||||||||||||||||||||||||
2015 | 2014 | 2015 | 2014 | |||||||||||||||||||||||||||||||||||||||||
Products and services revenue |
$ | 11,835 | $ | 10,140 | $ | 22,586 | $ | 21,619 | ||||||||||||||||||||||||||||||||||||
License fees and royalty revenue |
34 | 46 | 138 | 85 | ||||||||||||||||||||||||||||||||||||||||
Net revenue |
11,869 | 10,186 | 22,724 | 21,704 | ||||||||||||||||||||||||||||||||||||||||
Cost of revenue |
8,168 | 6,457 | 15,813 | 14,034 | ||||||||||||||||||||||||||||||||||||||||
Gross profit |
3,701 | 3,729 | 6,911 | 7,670 | ||||||||||||||||||||||||||||||||||||||||
Operating expenses: |
||||||||||||||||||||||||||||||||||||||||||||
Sales and marketing |
4,743 | 3,569 | 9,497 | 8,024 | ||||||||||||||||||||||||||||||||||||||||
General and administrative |
3,916 | 5,310 | 6,503 | 8,393 | ||||||||||||||||||||||||||||||||||||||||
Engineering and development |
1,974 | 978 | 3,777 | 1,951 | ||||||||||||||||||||||||||||||||||||||||
Excise tax |
97 | 64 | 153 | 129 | ||||||||||||||||||||||||||||||||||||||||
Legal settlement |
| | (731 | ) | | |||||||||||||||||||||||||||||||||||||||
Total operating expenses |
10,730 | 9,921 | 19,199 | 18,497 | ||||||||||||||||||||||||||||||||||||||||
Loss from operations |
(7,029 | ) | (6,192 | ) | (12,288 | ) | (10,827 | ) | ||||||||||||||||||||||||||||||||||||
Gain (loss) on foreign currency
transactions |
1 | (33 | ) | (129 | ) | (31 | ) | |||||||||||||||||||||||||||||||||||||
Interest income (expense), net |
23 | (185 | ) | 23 | (415 | ) | ||||||||||||||||||||||||||||||||||||||
Non-operating loss, net |
24 | (218 | ) | (106 | ) | (446 | ) | |||||||||||||||||||||||||||||||||||||
Loss before income tax provision
(benefit) |
(7,005 | ) | (6,410 | ) | (12,394 | ) | (11,273 | ) | ||||||||||||||||||||||||||||||||||||
Income tax provision (benefit) |
36 | 29 | 83 | 53 | ||||||||||||||||||||||||||||||||||||||||
Net loss |
$ | (7,041 | ) | $ | (6,439 | ) | $ | (12,477 | ) | $ | (11,326 | ) | ||||||||||||||||||||||||||||||||
Net loss per share: |
||||||||||||||||||||||||||||||||||||||||||||
Basic |
$ | (0.12 | ) | $ | (0.17 | ) | $ | (0.21 | ) | $ | (0.31 | ) | ||||||||||||||||||||||||||||||||
Diluted |
$ | (0.12 | ) | $ | (0.17 | ) | $ | (0.21 | ) | $ | (0.31 | ) | ||||||||||||||||||||||||||||||||
Shares used in the calculation of net
loss per share: |
||||||||||||||||||||||||||||||||||||||||||||
Basic |
58,180 | 37,629 | 58,163 | 37,045 | ||||||||||||||||||||||||||||||||||||||||
Diluted |
58,180 | 37,629 | 58,163 | 37,045 | ||||||||||||||||||||||||||||||||||||||||
|
BIOLASE, INC. | ||||||||||||||||||||
CONSOLIDATED BALANCE SHEETS | ||||||||||||||||||||
(in thousands, except per share data) | ||||||||||||||||||||
June 30 | December 31 | |||||||||||||||||||
- | - | |||||||||||||||||||
2015 | 2014 | |||||||||||||||||||
ASSETS |
(unaudited) |
(audited) |
||||||||||||||||||
Current assets: |
||||||||||||||||||||
Cash and cash equivalents |
$ | 19,922 | $ | 31,560 | ||||||||||||||||
Restricted cash equivalent |
200 | | ||||||||||||||||||
Accounts receivable, less allowance of $1,987 in 2015
and $1,711 in 2014 |
9,778 | 9,004 | ||||||||||||||||||
Inventory, net |
13,680 | 12,508 | ||||||||||||||||||
Prepaid expenses and other current assets |
1,631 | 1,726 | ||||||||||||||||||
Total current assets |
45,211 | 54,798 | ||||||||||||||||||
Property, plant and equipment, net |
2,366 | 1,295 | ||||||||||||||||||
Intangible assets, net |
79 | 114 | ||||||||||||||||||
Goodwill |
2,926 | 2,926 | ||||||||||||||||||
Other assets |
761 | 270 | ||||||||||||||||||
Total assets |
$ | 51,343 | $ | 59,403 | ||||||||||||||||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||||||||||||||
Current liabilities: |
||||||||||||||||||||
Accounts payable |
$ | 8,849 | $ | 8,357 | ||||||||||||||||
Accrued liabilities |
5,913 | 5,188 | ||||||||||||||||||
Customer deposits |
96 | 112 | ||||||||||||||||||
Deferred revenue, current portion |
3,050 | 2,494 | ||||||||||||||||||
Total current liabilities |
17,908 | 16,151 | ||||||||||||||||||
Deferred tax liabilities |
708 | 677 | ||||||||||||||||||
Deferred revenue, long-term |
201 | | ||||||||||||||||||
Capital lease obligation |
238 | | ||||||||||||||||||
Warranty accrual, long-term |
868 | 519 | ||||||||||||||||||
Other liabilities, long-term |
365 | | ||||||||||||||||||
Total liabilities |
20,288 | 17,347 | ||||||||||||||||||
Stockholders equity: |
||||||||||||||||||||
Preferred stock, par value $0.001 |
| | ||||||||||||||||||
Common stock, par value $0.001 |
58 | 58 | ||||||||||||||||||
Additional paid-in capital |
186,907 | 185,231 | ||||||||||||||||||
Accumulated other comprehensive loss |
(757 | ) | (557 | ) | ||||||||||||||||
Accumulated deficit |
(155,153 | ) | (142,676 | ) | ||||||||||||||||
Total stockholders equity |
31,055 | 42,056 | ||||||||||||||||||
Total liabilities and stockholders equity |
$ | 51,343 | $ | 59,403 | ||||||||||||||||
|
BIOLASE, INC. | ||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of GAAP Net Loss to Non-GAAP Net Loss | ||||||||||||||||||||||||||||||||||||||||||||
(unaudited, in thousands, except per share data) | ||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||||||||||||||||||
June 30 | June 30 | |||||||||||||||||||||||||||||||||||||||||||
2015 | 2014 | 2015 | 2014 | |||||||||||||||||||||||||||||||||||||||||
GAAP net
loss |
$ | (7,041 | ) | $ | (6,439 | ) | $ | (12,477 | ) | $ | (11,326 | ) | ||||||||||||||||||||||||||||||||
Adjustments: |
||||||||||||||||||||||||||||||||||||||||||||
Interest (income) expense, net... |
(2 | 3) | 18 | 5 | (2 | 3) | 415 | |||||||||||||||||||||||||||||||||||||
Income tax (benefit) provision..................... |
36 | 29 | 83 | 53 | ||||||||||||||||||||||||||||||||||||||||
Depreciation and amortization expense |
166 | 177 | 324 | 352 | ||||||||||||||||||||||||||||||||||||||||
Stock-based compensation, other equity instruments,
and other non-cash compensation expense..................... |
935 | 338 | 1,635 | 709 | ||||||||||||||||||||||||||||||||||||||||
Non-GAAP net
loss... |
$ | (5,927 | ) | $ | (5,710 | ) | $ | (10,458 | ) | $ | (9,797 | ) | ||||||||||||||||||||||||||||||||
GAAP net loss per share, basic and diluted... |
$ | (0.12 | ) | $ | (0.17 | ) | $ | (0.21 | ) | $ | (0.31 | ) | ||||||||||||||||||||||||||||||||
Adjustments: |
||||||||||||||||||||||||||||||||||||||||||||
Interest
expense |
| 0.01 | | 0.02 | ||||||||||||||||||||||||||||||||||||||||
Income tax (benefit) provision..................... |
| | | | ||||||||||||||||||||||||||||||||||||||||
Depreciation and amortization expense |
| | | 0.01 | ||||||||||||||||||||||||||||||||||||||||
Stock-based compensation, other equity instruments,
and other non-cash compensation expense..................... |
0.02 | 0.01 | 0.03 | 0.02 | ||||||||||||||||||||||||||||||||||||||||
Non-GAAP net loss per share, basic and diluted |
$ | (0.10 | ) | $ | (0.15 | ) | $ | (0.18 | ) | $ | (0.26 | ) | ||||||||||||||||||||||||||||||||
# # # #
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bombardier Announces the Election of its Board of Directors
- Belite Bio Announces $25 Million Registered Direct Offering
- Guanajuato Silver Announces Brokered LIFE Offering of Units
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!